Summit Therapeutics announced today that it will proceed with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial evaluating the utrophin modulator ezutromid, subject to regulatory approval.
This follows an interim review of the safety and tolerability data from the ongoing trial by an independent Data…Continue
Added by PPMD on March 27, 2017 at 11:25am — No Comments
Health insurance is a contract between you and an insurance company. Health insurance helps pay your medical bills when you need care.
There are two major types of health insurance:
PPMD is pleased to learn that the FDA has completed its review and concluded that Akashi Therapeutics may resume clinical development of HT-100 (delayed-release halofuginone) in people with Duchenne (click here to read Akashi's press release). Preventing fibrosis is an important target and an essential piece of a combination of therapies that will be…Continue
Added by PPMD on March 22, 2017 at 9:00am — No Comments
“Who’s on first?”
Remember that classic Abbott & Costello routine? Well, trying to track the quickly-shifting healthcare bill has felt much like watching that routine. Complex, confusing, and exhausting. But the stakes here are no laughing matter.
Added by Annie Kennedy on March 21, 2017 at 10:00am — No Comments
The European Neuromuscular Center (ENMC) is a global organization that gathers expertise from around the world to address many issues and concerns of, and advance research and treatments for, neuromuscular…Continue
Added by Kathi Kinnett on March 17, 2017 at 4:00pm — No Comments
Today we learned that PTC Therapeutics has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC …Continue
Added by PPMD on March 16, 2017 at 11:00am — No Comments
Added by PPMD on March 6, 2017 at 9:00am — No Comments
This week, PPMD convened Duchenne industry partners, experts in adaptive trial design and biostatistics, and innovative partners from outside of the Duchenne world who’ve revolutionized their clinical trial spaces for the second meeting of our Duchenne Drug Development Roundtable's 3-part meeting series, focusing on Clinical…Continue
Added by Abby Bronson on March 3, 2017 at 10:00am — No Comments
Added by Annie Kennedy on February 27, 2017 at 7:30pm — No Comments
An Overview of Your Impact in Action
PPMD Grant Awards in the last Quarter of 2016 and first part of 2017.
PPMD Launches Long-Term…Continue
Added by Abby Bronson on February 24, 2017 at 1:29pm — No Comments
Added by PPMD on February 16, 2017 at 12:00pm — No Comments
In light of the pause in commercialization of EMFLAZA™ (deflazacort)…Continue
Added by PPMD on February 15, 2017 at 1:30pm — No Comments
Children’s Hospital Los Angeles (CHLA) marked our first stop of the New Year on PPMD’s 2017 Every Single One Tour, held on January 21, 2017. We were thrilled to not only be holding another tour stop at one of …Continue
Added by PPMD on February 15, 2017 at 10:30am — No Comments
UPDATE: February 13, 2017, 5:10 PM -- An additional statement from Marathon has been added to the blog
Added by PPMD on February 13, 2017 at 4:00pm — No Comments
UPDATE 2/10: Marathon has released links to new resources, including the EMFLAZA website (https://emflaza.com) and a Patient Support FAQ document (…Continue
Following decades of strategic advocacy, research investment, and biopharmaceutical development, the U.S. Duchenne community recently arrived in the post-approval space and is poised to receive additional novel therapies from a robust innovation pipeline.…
Added by PPMD on February 7, 2017 at 1:57pm — No Comments
Better. Faster. Now.
How do we apply the ‘regulatory learnings’ of the past 18 months back into our robust Duchenne pipeline to ensure as many effective therapies yield from our pipeline as possible?
Under the leadership of PPMD's Duchenne Drug Development Roundtable (DDDR), our community is determined to figure that out. Today is the first of a…Continue
Added by Abby Bronson on February 1, 2017 at 10:00am — No Comments
Added by PPMD on January 31, 2017 at 4:08pm — No Comments
Added by Pat Furlong on January 30, 2017 at 10:00am — No Comments
Added by PPMD on January 19, 2017 at 11:30am — No Comments